BIONTECH SE

NASDAQ: BNTX (BioNTech SE)

最近更新时间: 4天之前, 10:18PM

106.62

1.08 (1.02%)

前收盘价格 105.54
收盘价格 107.01
成交量 631,255
平均成交量 (3个月) 1,209,110
市值 26,754,236,416
预期市盈率 (P/E Forward) 7.04
价格/销量 (P/S) 7.40
股市价格/股市净资产 (P/B) 1.32
52周波幅
81.20 (-23%) — 124.49 (16%)
利润日期 3 Nov 2025
营业毛利率 -27.89%
营业利益率 (TTM) -270.46%
稀释每股收益 (EPS TTM) -3.72
季度收入增长率 (YOY) -2.60%
季度盈利增长率 (YOY) -43.30%
总债务/股东权益 (D/E MRQ) 1.55%
流动比率 (MRQ) 10.18
营业现金流 (OCF TTM) -255.70 M
杠杆自由现金流 (LFCF TTM) -335.98 M
资产报酬率 (ROA TTM) -3.67%
股东权益报酬率 (ROE TTM) -3.94%

市场趋势

短期 中期
行业 Biotechnology (US) 看涨 混合的
Biotechnology (全球的) 看涨 混合的
股票 BioNTech SE 看涨 看跌

AIStockmoo 评分

1.6
分析师共识 5.0
内部交易活动 NA
价格波动 -1.0
技术平均移动指标 0.0
技术振荡指标 2.5
平均 1.63

相关股票

股票 市值 DY P/E(TTM) P/B
BNTX 27 B - - 1.32
BLTE 7 B - - 24.96
GPCR 5 B - - 7.45
LEGN 3 B - - 3.20
MAZE 2 B - - 5.71
ELVN 2 B - - 3.67

BioNTech is a Germany-based biotechnology company that focuses on developing cancer therapeutics, including individualized immunotherapy, as well as vaccines for infectious diseases, including covid. The company's oncology pipeline contains several classes of drugs, including mRNA-based drugs to encode antigens, neoantigens, cytokines, and antibodies; cell therapies; bispecific antibodies; and antibody-drug conjugates, or ADCs. BioNTech is partnered with several large pharmaceutical companies, including Roche, Eli Lilly, Pfizer, Sanofi, and Genmab. Covid vaccine Comirnaty is its first commercialized product.

部门 Healthcare
行业 Biotechnology
内部持股比例 62.69%
机构持股比例 22.24%
52周波幅
81.20 (-23%) — 124.49 (16%)
目标价格波幅
140.00 (31%) — 142.00 (33%)
142.00 (Goldman Sachs, 33.18%) 购买
141.00 (32.25%)
140.00 (HC Wainwright & Co., 31.31%) 购买
平均值 141.00 (32.25%)
总计 2 购买
平均价格@调整类型 107.04
公司 日期 目标价格 调整类型 价格@调整类型
Goldman Sachs 16 Jan 2026 142.00 (33.18%) 购买 109.00
HC Wainwright & Co. 10 Nov 2025 140.00 (31.31%) 购买 105.07

该时间范围内无数据。

日期 类型 细节
28 Jan 2026 公告 BioNTech Announces Appointment of Kylie Jimenez to Management Board as Chief People Officer
12 Jan 2026 公告 BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
12 Jan 2026 公告 BioNTech Provides Strategic Business Update and Outlines 2026 Areas of Focus at 44th Annual J.P. Morgan Healthcare Conference
18 Dec 2025 公告 BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
18 Dec 2025 公告 BioNTech Closes Acquisition of CureVac N.V. Including Subsequent Offering Period to Strengthen its Unique Position in the mRNA Field
09 Dec 2025 公告 BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
09 Dec 2025 公告 BioNTech and Bristol Myers Squibb Present First Global Phase 2 Data for PD-L1xVEGF-A Bispecific Antibody Pumitamig Showing Encouraging Efficacy in Advanced Triple-Negative Breast Cancer
06 Dec 2025 公告 BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
06 Dec 2025 公告 BioNTech and OncoC4 Announce Clinically Meaningful Overall Survival Benefit for Selective Treg Modulator Gotistobart in Patients with Previously Treated Squamous Non-Small Cell Lung Cancer
03 Dec 2025 公告 BioNTech Achieves Minimum Condition in CureVac Exchange Offer
03 Dec 2025 公告 BioNTech Achieves Minimum Condition in CureVac Exchange Offer
26 Nov 2025 公告 BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
26 Nov 2025 公告 BioNTech Shares Progress on Exchange Offer for CureVac Shares and Highlights December 3, 2025, at 9:00 a.m. Eastern Time Expiration
显示更多
除息日 公告日期 支付日期 详情
02 Jun 2022 - 17 Jun 2022 2.111 现金

每年股息收益率

年份 每年总股息 ($) 频率/年份 收益率 %
2022 2.11 1 1.41

支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。

投资组合

AI 建议策略模板

自定义的价格提醒

风险概况

| | | | |
很保守
适度保守
中等
中等风险
激进风险
安全边际 (EP)
部分利润 (TP1)
目标利润 (TP2)
最大损失 (SL)

免责声明:以上内容仅供参考,并非投资建议。请咨询合格的财务顾问。

开始购买价格 (EP)

第一个目标价格赚取利润 (TP1)

第二个目标价格赚取利润 (TP2)

停止损失价格 (SL)

52周波幅范围
 
52WL
 
52WH
SL
EP
TP1
TP2

所有提醒价格都在52周波幅范围内

已实现利润 -
未实现利润 -
收到股息 2026 -
利润总额 -
平均回报 -
数量(购买) -
平均价格(购买) -
数量(卖出) -
平均价格(卖出) -
没有符合您标准的股票